PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 23341496-8 2013 Furthermore, administration of GW-9508 decreased the hepatic expression of fetuin-A in HFD mice significantly and regulated high-glucose- or palmitate-induced fetuin-A expression to increase insulin sensitivity through a GPR40/PLC/PKC pathway in HepG2 cells. GW9508 31-38 free fatty acid receptor 1 Mus musculus 221-226 26699911-4 2016 To further investigate this hypothesis, biological effects of GW9508, a synthetic agonist for GPR40, was first tested on osteoblast differentiation parameters. GW9508 62-68 free fatty acid receptor 1 Mus musculus 94-99 26699911-10 2016 Nevertheless, a significant increase in OPG expression was observed upon GW9508 treatment that contribute to explain the GPR40-related osteoporosis prevention. GW9508 73-79 free fatty acid receptor 1 Mus musculus 121-126 25576830-7 2015 Furthermore, in vivo GW9508 administration rescued estrogen-deficient bone loss, indicating the essential role of the GPR40 receptor. GW9508 21-27 free fatty acid receptor 1 Mus musculus 118-123 25281202-10 2014 BCAO-induced mechanical hyperalgesia was significantly decreased by intracerebroventricular injection of docosahexaenoic acid or GW9508, a GPR40 agonist; furthermore, these effects were reversed by GW1100, a GPR40 antagonist. GW9508 129-135 free fatty acid receptor 1 Mus musculus 139-144 25281202-10 2014 BCAO-induced mechanical hyperalgesia was significantly decreased by intracerebroventricular injection of docosahexaenoic acid or GW9508, a GPR40 agonist; furthermore, these effects were reversed by GW1100, a GPR40 antagonist. GW9508 129-135 free fatty acid receptor 1 Mus musculus 208-213 26071852-1 2015 Previous studies have shown that the administration of docosahexaenoic acid (DHA) or GW9508, a GPR40/FFA1 (free fatty acid receptor) agonist, facilitates beta-endorphin release in the arcuate nucleus of the hypothalamus in mice. GW9508 85-91 free fatty acid receptor 1 Mus musculus 95-100 25889021-3 2015 RESULTS: Intrathecal injection of GPR40 agonist (MEDICA16 or GW9508) dose-dependently reduced ipsilateral mechanical allodynia in CFA and SNL models and thermal hyperalgesia in carrageenan model. GW9508 61-67 free fatty acid receptor 1 Mus musculus 34-39 25008074-5 2014 Knockdown of hepatic Ffar1 by lentiviral vectors containing short hairpin RNA targeted to Ffar1 diminished the effect of GW9508 in HFD mice. GW9508 121-127 free fatty acid receptor 1 Mus musculus 21-26 25008074-5 2014 Knockdown of hepatic Ffar1 by lentiviral vectors containing short hairpin RNA targeted to Ffar1 diminished the effect of GW9508 in HFD mice. GW9508 121-127 free fatty acid receptor 1 Mus musculus 90-95 24758921-3 2014 A repeated but not a single intracerebroventricular administration of the GPR40 agonist, GW9508, reduced the duration of immobility behavior. GW9508 89-95 free fatty acid receptor 1 Mus musculus 74-79 24349089-9 2013 The intracerebroventricular injection of DHA (50 microg) and GW9508 (1.0 microg), a GPR40-selective agonist, significantly reduced mechanical allodynia and thermal hyperalgesia at day 7, but not at day 1, after CFA injection. GW9508 61-67 free fatty acid receptor 1 Mus musculus 84-89 24349089-11 2013 The protein expression of GPR40 was colocalized with that of beta-endorphin and proopiomelanocortin, and a single intracerebroventricular injection of GW9508 (1.0 microg) significantly increased the number of neurons double-stained for c-Fos and proopiomelanocortin in the arcuate nucleus of the hypothalamus. GW9508 151-157 free fatty acid receptor 1 Mus musculus 26-31 23335512-7 2013 In addition, in vivo administration of GW9508 counteracted ovariectomy-induced bone loss in wild-type but not GPR40(-/-) mice, enlightening the obligatory role of the GPR40 receptor. GW9508 39-45 free fatty acid receptor 1 Mus musculus 167-172 23335512-6 2013 The GPR40-dependent effect of GW9508 was confirmed using shRNA interference in osteoclast precursors and GPR40(-/-) primary cell cultures. GW9508 30-36 free fatty acid receptor 1 Mus musculus 4-9 23335512-6 2013 The GPR40-dependent effect of GW9508 was confirmed using shRNA interference in osteoclast precursors and GPR40(-/-) primary cell cultures. GW9508 30-36 free fatty acid receptor 1 Mus musculus 105-110 22137657-7 2012 injection of DHA (25 and 50mug/mouse) and GW9508 (a GPR40- and GPR120-selective agonist; 0.1 and 1.0mug/mouse) significantly reduced formalin-induced pain behavior. GW9508 42-48 free fatty acid receptor 1 Mus musculus 52-57 34489696-6 2021 Interestingly, local application of a FFAR1 agonist, GW9508, markedly augmented the striatal 5-HT release in FFAR1 wild-type (+/+) mice, whereas topical application of a FFAR1 antagonist, GW1100, significantly reduced the 5-HT release. GW9508 53-59 free fatty acid receptor 1 Mus musculus 38-43 16702987-3 2006 Here, we present the first description of GW9508, a small-molecule agonist of the fatty acid receptors GPR40 and GPR120. GW9508 42-48 free fatty acid receptor 1 Mus musculus 103-108 16702987-9 2006 GW1100 dose dependently inhibited GPR40-mediated Ca2+ elevations stimulated by GW9508 and linoleic acid (pIC50 values of 5.99+/-0.03 and 5.99+/-0.06, respectively). GW9508 79-85 free fatty acid receptor 1 Mus musculus 34-39 34297968-3 2021 GPR40 agonist GW9508 and antagonist GW1100 were given by i.g injection to activate/inhibit the GPR40 receptor respectively in the gut of AD mouse which illustrated the function and mechanism of GPR40 receptor in ameliorating AD symptoms by external treatment of encephalopathy. GW9508 14-20 free fatty acid receptor 1 Mus musculus 0-5 34297968-3 2021 GPR40 agonist GW9508 and antagonist GW1100 were given by i.g injection to activate/inhibit the GPR40 receptor respectively in the gut of AD mouse which illustrated the function and mechanism of GPR40 receptor in ameliorating AD symptoms by external treatment of encephalopathy. GW9508 14-20 free fatty acid receptor 1 Mus musculus 95-100 34297968-3 2021 GPR40 agonist GW9508 and antagonist GW1100 were given by i.g injection to activate/inhibit the GPR40 receptor respectively in the gut of AD mouse which illustrated the function and mechanism of GPR40 receptor in ameliorating AD symptoms by external treatment of encephalopathy. GW9508 14-20 free fatty acid receptor 1 Mus musculus 194-199 34489696-6 2021 Interestingly, local application of a FFAR1 agonist, GW9508, markedly augmented the striatal 5-HT release in FFAR1 wild-type (+/+) mice, whereas topical application of a FFAR1 antagonist, GW1100, significantly reduced the 5-HT release. GW9508 53-59 free fatty acid receptor 1 Mus musculus 109-114 29777569-2 2018 The FFA1 agonist GW9508 has great potential for the treatment of type 2 diabetes mellitus, but it has been suffering from high plasma clearance probably because the phenylpropanoic acid is vulnerable to beta-oxidation. GW9508 17-23 free fatty acid receptor 1 Mus musculus 4-8 31809762-3 2020 GPR40 agonist GW9508 and antagonist GW1100 were respectively given by i.c.v. GW9508 14-20 free fatty acid receptor 1 Mus musculus 0-5 31129318-3 2019 METHODS: The present study investigates the influence of prolonged treatment with GW9508 - agonist of FFAR1 and FFAR4 - on the development of atherosclerosis plaque in apoE-knockout mice, using morphometric and molecular methods. GW9508 82-88 free fatty acid receptor 1 Mus musculus 102-107 31129318-6 2019 CONCLUSIONS: Prolonged administration of GW9508 resulted in significant amelioration of atherogenesis, providing evidence that the strategy based on macrophage phenotype switching toward an M2-like activation state via stimulation of FFAR1/FFAR4 receptors holds promise for a new approach to the prevention or treatment of atherosclerosis. GW9508 41-47 free fatty acid receptor 1 Mus musculus 234-239 29981843-5 2018 Next, we demonstrated that chronic treatment with docosahexaenoic acid (DHA) or the synthetic GPR40 agonist, GW9508, significantly alleviates cognitive functions in mice, which correlates with increased BDNF expression in the hippocampus. GW9508 109-115 free fatty acid receptor 1 Mus musculus 94-99 29568424-2 2017 Herein, we describe the design and synthesis of FAAzo-10, a light-controllable GPR40 agonist based on Gw-9508. GW9508 102-109 free fatty acid receptor 1 Mus musculus 79-84 28446241-12 2017 Intracerebroventricular treatment with the GPR120- and GPR40-specific agonists TUG1197 and TUG905, respectively, resulted in milder effects than those produced by GW9508. GW9508 163-169 free fatty acid receptor 1 Mus musculus 55-60 26976092-9 2016 All GPR40 receptor agonist GW9508, treatment groups enhanced the learning and memory ability in Step-through passive test, Morris water maze test, Hole board discrimination test, Novel object recognition test. GW9508 27-33 free fatty acid receptor 1 Mus musculus 4-9